FDA Drug recall D-0720-2021
Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, N…
- FDA Drug
- Class II
- terminated
- Published 2021-08-18
On 2021-08-18 the FDA classified a Class II recall of Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, N… by Eli Lilly And, citing cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0720-2021 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2021-06-29 |
| Published | 2021-08-18 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Eli Lilly And |
| Distribution | IN, MS, OH |
Product
Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01
Reason
cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.
Identifiers
| code_info | Lot # 197 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0720-2021%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.